Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
Christine I. Wooddell, Madison, WI (US); David L. Lewis, Madison, WI (US); Darren H. Wakefield, Fitchburg, WI (US); Lauren Almeida, Madison, WI (US); and Steven B. Kanner, Berkeley, CA (US)
Assigned to Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US)
Filed by Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US)
Filed on Jun. 8, 2022, as Appl. No. 17/834,988.
Application 15/990,330 is a division of application No. 14/740,307, filed on Jun. 16, 2015, granted, now 10,006,025.
Application 17/834,988 is a continuation of application No. 16/428,431, filed on May 31, 2019, granted, now 11,384,355.
Application 16/428,431 is a continuation of application No. 15/990,330, filed on May 25, 2018, abandoned.
Claims priority of provisional application 62/013,288, filed on Jun. 17, 2014.
Prior Publication US 2023/0002768 A1, Jan. 5, 2023
1. An RNA interference (RNAi) trigger molecule capable of inhibiting the expression of an alpha-1 antitrypsin gene, wherein the RNAi trigger molecule comprises a sense strand sequence and an antisense strand sequence, wherein the sense strand sequence and the antisense strand sequence form a sequence pair of SEQ ID NOs: 16/28 or a sequence meroduplex of SEQ ID NOs: 16/29/44.